Ropes & Gray Helps Pfizer Buy Anti-Scar Drug Co.

Law360, New York (November 22, 2011, 2:59 PM EST) -- Pfizer Inc. has agreed to purchase Excaliard Pharmaceuticals Inc., a privately held specialty drug company that focuses on treatments for skin scars, for an undisclosed amount, the drug giant announced Tuesday.

Despite not announcing a purchase price, Pfizer said that it will give Excaliard an upfront payment and contingent payments for meeting certain milestones. Excaliard's lead product, EXC 001, is in Phase 2 testing, and will fill a hole in the treatment of excessive scarring.

There are no U.S. Food and Drug Administration-approved treatments for skin...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.